

Interlocutory Orders, Etc.

IN THE MATTER OF

HIKMA PHARMACEUTICALS PLC

Docket No. C-4568. Order, December 6, 2017

Letter notifying Hikma Pharmaceuticals plc of the Commission's decision to waive prior approval and public comment regarding modifications to the Supply Agreement and Asset Purchase Agreement.

LETTER WAIVING PRIOR APPROVAL AND COMMENT FOR
MODIFICATIONS TO AGREEMENTS

Maria Raptis, Esq.
Skadden, Arps, Slate, Meagher & Flom LLP

Re: In the Matter of *Hikma Pharmaceuticals plc*,
Docket No. C-4568

Dear Ms. Raptis:

This letter refers to an application for approval that Hikma Pharmaceuticals plc ("Hikma") filed on October 23, 2017, which requested Commission approval of a proposed amendment to the Supply Agreement (Prednisone) and Asset Purchase Agreement, incorporated by reference into the Decision and Order entered into in this case.¹

After consideration of Hikma's application and pursuant to the authority delegated to me under Rule 2.41(f)(5)(ii) of the Commission's Rules of Practice, 16 C.F.R. § 2.41(f)(5)(ii), I hereby waive the requirements for Commission approval and the public comment period for the amendment to the Supply Agreement and Asset Purchase Agreement described in Hikma's application.

If you have further questions, please contact David von Nirschl, the Compliance staff attorney assigned to this matter.

¹ Order ¶¶ I.R.R., II.A., and VI.

Interlocutory Orders, Etc.

David von Nirschl can be reached at 202-326-3213 or
dnirschl@ftc.gov.

Interlocutory Orders, Etc.

IN THE MATTER OF

FRESENIUS MEDICAL CARE AG & CO. KGAA

Docket No. C-4348. Order, December 15, 2017

Letter Order approving respondent's application to establish a dialysis clinic

LETTER ORDER APPROVING APPLICATION

Mr. Brian F. Burke, Esq.
Baker & McKenzie LLP

Re: *Fresenius Medical Care AG & CO. KGaA*,
Docket No. C-4348

Dear Mr. Burke,

Pursuant to Rule 2.41(f) of the Commission's Rules of Practice, the Commission has determined to approve the Application of Fresenius Medical Care AG & CO. KGaA ("Fresenius") (October 4, 2017) to establish a dialysis clinic at 5311 Clyde Park Avenue, SW, Wyoming, Michigan, a location that was previously divested to DSI by Fresenius as a *de novo* dialysis clinic pursuant to the Commission Order in the above matter. The property was never developed into a dialysis clinic and has been vacant for over five years. In according its approval to Fresenius's Application, the Commission has relied upon the information submitted by Fresenius, and the Commission has assumed that information to be accurate and complete.

By direction of the Commission.